The 2026 Japan Prize Award Ceremony Is Held With Their Majesties the Emperor and Empress of Japan in Attendance
14.4.2026 19:00:00 CEST | Business Wire | Press Release
The Japan Prize Foundation (President: Ryozo Nagai) held an award ceremony on Tuesday, April 14, at the New National Theatre, Tokyo in Tokyo's Shibuya Ward to confer the Japan Prize on scientists who have made creative and dramatic achievements in the global scientific and technological fields and who have contributed significantly to realizing peace and prosperity for all humanity.
Cynthia Dwork, Ph.D. (USA), the winner in the field of Electronics, Information, and Communication, and Shizuo Akira, Ph.D. (Japan) and Zhijian “James” Chen, Ph.D. (USA), the winners in the field of Life Science, were in attendance at the award ceremony, and each field was awarded 100 million Yen together with a certificate and a medal.
The winners of the 2026 Japan Prize were recommended by approximately 16,000 prominent scientists and engineers from around the world and decided by a rigorous examination taking about 1 year. The Foundation received 107 nominations for the field of Electronics, Information, and Communication and 185 nominations for the field of Life Science. This year's winners were selected from that total of 292 candidates.
The ceremony was attended by about 600 guests, starting with Their Majesties the Emperor and Empress, heads of the three branches of government and other related officials, and representatives from various other elements of society. His Majesty the Emperor delivered remarks, followed by speeches by the 3 winners and congratulatory remarks by Sekiguchi, President of the House of Councillors.
This year's award ceremony can be viewed from the links below.
Japanese Version: https://youtube.com/live/jllrOVOX6jI
English Version: https://youtube.com/live/flkjnpPAtok
Profile photos of the Japan Prize winners and photos from the day of the award ceremony will be uploaded to this link.
https://www.japanprize.jp/en/press_photo.html
*When publishing these photos, please include a credit that reads "Courtesy of: Japan Prize."
About the Japan Prize
The establishment of the Japan Prize in 1981 was motivated by the Japanese government's desire to create an internationally recognized award that would contribute to scientific and technological development around the world. With the support of numerous donations, the Japan Prize Foundation received endorsement from the Cabinet Office in 1983. The Japan Prize is awarded to scientists and engineers from around the world who have made creative and dramatic achievements that help progress their fields and contribute significantly to realizing peace and prosperity for all humanity. Researchers in all fields of science and technology are eligible for the award, with two fields selected each year in consideration of current trends in scientific and technological development. In principle, one individual in each field is recognized with the award, and receives a certificate, a medal, and a monetary prize. Each award ceremony is attended by Their Majesties the Emperor and Empress, heads of the three branches of government and other related officials, and representatives from various other elements of society.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260414866015/en/
Contacts
For inquiries about this release:
The Japan Prize Public Relations Office
E-mail: japanprize@ml.prap.co.jp
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press Release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press Release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom